Skip to main content
Normal View

Medicinal Products

Dáil Éireann Debate, Wednesday - 27 May 2026

Wednesday, 27 May 2026

Questions (280)

Pádraig O'Sullivan

Question:

280. Deputy Pádraig O'Sullivan asked the Minister for Health the proportion of innovative oncology medicines approved at European level that are currently available and reimbursed in Ireland; the reason this proportion remains at approximately 25% given that the 180-day reimbursement timeline has been a legislative requirement under the Health Act 2013 for over a decade; the accountability measures that will be put in place to ensure the phased timeline under the new framework agreement is met at each stage; and if she will make a statement on the matter. [40640/26]

View answer

Written answers

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Share